Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019
Q2 FY20 results · Jul–Sep 2019
Jubilant Pharmova reported revenue from operations of ₹2,265.93 crore (down 0.2% from Q2 FY19) and net profit of ₹249.39 crore (up 18.9% from Q2 FY19) for Q2 FY20 (Jul–Sep 2019), on a consolidated basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,265.93 | 2,269.49 | −0.2% | 2,181.86 | +3.9% |
| Other income | 12.26 | 3.83 | +220.1% | 9.70 | +26.4% |
| Total income | 2,278.19 | 2,273.32 | +0.2% | 2,191.56 | +4.0% |
| Profit before tax | 292.23 | 301.81 | −3.2% | 269.03 | +8.6% |
| Net profit for the period | 249.39 | 209.77 | +18.9% | 184.98 | +34.8% |
| EPS, basic (₹) | 15.66 | 13.50 | +16.0% | 11.61 | +34.9% |
| Net margin (%) | 11.0 | 9.2 | 8.5 |
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 757.54 | 887.27 | −14.6% | 789.82 | −4.1% |
| Other income | 79.08 | 63.80 | +23.9% | 5.94 | 13x |
| Total income | 836.62 | 951.07 | −12.0% | 795.76 | +5.1% |
| Profit before tax | 106.20 | 91.21 | +16.4% | 47.32 | +124.4% |
| Net profit for the period | 143.07 | 79.61 | +79.7% | 32.26 | +343.5% |
| EPS, basic (₹) | 8.98 | 5.00 | +79.6% | 2.03 | +342.4% |
| Net margin (%) | 18.9 | 9.0 | 4.1 |
Consolidated
- Filed with BSE
- 26 Oct 2019, 11:25 IST
- Board meeting
- 25 Oct 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 26 Oct 2019, 11:25 IST
- Board meeting
- 25 Oct 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE